Finn
CLBT Security software · Digital forensics · Public sector · SaaS · Thesis updated November 15, 2026

U.S. federal rebound and early AI adoption fuel a recovery

01 Running thesis

Cloud clearance meets execution risk

The company rebounded strongly in the third quarter of 2026 after a mid year execution stumble. The critical U.S. federal segment returned to 18% growth, clearing up concerns about government spending freezes. To solve ongoing foreign entity procurement hurdles, the company announced plans to relocate its headquarters to the United States by the first half of 2027.

The bull case centers on massive market expansion through artificial intelligence. The Genesis AI product proved to be an immediate success, securing $2 million in annual recurring revenue during its first full quarter. Management believes the investigative AI market could reach roughly $12.5 billion over four years, which could easily double the size of the current business.

The bear case asks if this new product momentum can overcome isolated problem areas. The Corellium acquisition is deteriorating under a prolonged national security review, causing higher customer churn and freezing new sales. Additionally, as more customers finish upgrading to the Inseyets platform, the company will get less pricing uplift to drive near term growth. Profit margins also face ongoing pressure from a stronger Israeli shekel.

Nov 2026▲Q3 2026 showed a massive fundamental improvement. U.S. federal growth accelerated to 18%, Genesis AI reached $2 million in recurring revenue, and the company announced plans to relocate to the United States.
Aug 2026▼Q2 2026 introduced execution risk. The board appointed Shiv Ramji as CEO and management lowered full year guidance due to cloud procurement delays, though Genesis secured early paid revenue.
May 2026▲Q1 2026 strengthened the thesis. Cellebrite received FedRAMP High authorization, Genesis showed more than 500 registered users, and management sized investigative AI at roughly $12.5 billion over four years.
Mar 2026▲The 2025 Form 20-F confirmed strong execution, with revenue of $475.7 million, up 19% year over year. It also added more evidence of regulatory friction around encrypted device access.
Feb 2026▲Q4 2025 de-risked the core story as U.S. federal disruption moved behind the company and Inseyets reached 55% of the installed license base. The company also added Corellium and announced a move into drone forensics through SCG Canada.
Nov 2025▲Q3 2025 showed the U.S. federal flywheel starting to move again, helped by large agency expansions. Inseyets migration reached about 47%, and Guardian Investigate became a clearer early 2026 product catalyst.
Aug 2025→Q2 2025 was mixed. Tom Hogan became full-time CEO and Corellium plus FedRAMP sponsorship improved the long term story, but U.S. federal spending delays pushed the expected rebound into 2026.
May 2025→Q1 2025 showed healthy product adoption, with Inseyets above 30% of the installed base and cloud offerings near 20% of recurring revenue. Spending delays in U.S. federal and EMEA kept the near term view cautious.
02 Business model

Software sold to agencies

Cellebrite sells software to public sector agencies and some private companies. Public sector work is the center of the business. The 2025 filing says Public Sector Customers accounted for more than 90% of total revenue, and no single organization made up more than 5% of 2025 revenue.

Most sales are subscriptions. Customers pay for term licenses, software applications, support, and maintenance. Total license subscription revenue represented 90% of 2025 revenue, up from 88% in 2024. This makes revenue more repeatable than a pure hardware or services model. The launch of Genesis introduced a consumption based token model, adding flexible usage revenue.

The model works best when an agency starts with digital forensics and then adds tools for evidence storage, analytics, case management, and artificial intelligence. That is why Inseyets migration, Guardian adoption, and Genesis conversion are the key moving parts.

Where it can break is budget timing and permissions. Many buyers are government agencies, so spending can pause during program changes or audits. Being a foreign entity recently added procurement hurdles for cloud adoption in the U.S. and Europe, prompting the company to announce a planned relocation to the United States.

03 Product portfolio

From phones to full cases

Cash cow

Inseyets

Inseyets is the core digital forensics suite used to collect and review evidence from phones, computers, cloud apps, and vehicles. Management said 75% of the installed digital forensics base had converted to Inseyets by the end of Q3 2026.

Steady

Advanced lawful access

These tools help authorized users access locked devices under legal authority. They are valuable but sit closest to regulatory and device maker friction.

Growth engine

Guardian Forensics and Guardian Collaborate

Guardian products help store, share, review, and manage digital evidence. They push Cellebrite from device extraction into the larger workflow around a case.

Option

Guardian Investigate

Guardian Investigate is an AI powered system of record for case management. It is now in general availability and forms a major piece of the growth strategy.

Growth engine

Genesis

Genesis is Cellebrite’s agentic AI product for faster data insight. It operates on a consumption based token model and secured $2 million in annual recurring revenue in its first full quarter.

Option

Corellium

Corellium adds virtualization software for mobile security research and vulnerability work. The business is currently facing high churn while it awaits U.S. national security approval.

Option

SCG Canada drone forensics

SCG Canada gives Cellebrite tools to extract, decode, and view evidence from common drones. The acquisition adds an immediate entry into a growing market.

04 Business segments

Subscription carries the mix

Total subscription90%growing fast
Other non-recurring4%modest
Professional services6%flat

The structured mix uses fiscal 2025 revenue lines from the 2025 Form 20-F because the available filing section discloses revenue by type. Geography is still important, as the Americas is the largest region and U.S. federal growth recently accelerated to 18%.

05 Risk factors

What could still go wrong

Foreign entity status limits sales

High impact · Medium odds

Cellebrite is currently a foreign entity, which triggers extra review for cloud software contracts. The company plans to redomicile to the United States in 2027 to eliminate this friction. If the move is delayed or fails to satisfy regulators, growth could stall again.

We watchWatch management updates on the planned U.S. redomiciliation and cloud revenue growth rates.

AI adoption hits a wall

High impact · Medium odds

Genesis has early usage and generated $2 million in revenue in its first full quarter. However, the hard part is mass adoption. Management has a very large revenue target for artificial intelligence tools. If trial users do not become permanent paid seats, the story will stall.

We watchWatch paid Genesis customers, AI revenue disclosure, and any change to the $12.5 billion market target.

Corellium struggles under review

Medium impact · High odds

The Corellium business is deteriorating under a prolonged U.S. national security review. This review is causing higher customer churn and freezing new sales. Strict regulatory limits could permanently damage the value of the acquisition.

We watchWatch for a final national security agreement, mitigation terms, or a write down of the Corellium asset.

Device access becomes harder

High impact · Medium odds

Cellebrite relies on keeping pace with new phone hardware, operating systems, encryption, and app changes. Regulators and device makers can also push back on tools that access locked or protected data.

We watchWatch Apple and Android security updates, court rulings on lawful access, and customer reports of lower extraction success.

Shekel strength pinches margins

Low impact · High odds

Cellebrite reports in dollars, but a meaningful part of its costs are in Israeli shekels. A stronger shekel raises dollar reported expenses and can compress profit margins. Management calls this an ongoing near term headwind.

We watchWatch adjusted profit margins, dollar to shekel moves, and hedging commentary on earnings calls.
06 Quick answers

In one breath

What does Cellebrite actually do?

Cellebrite sells software that helps authorized users collect, decode, manage, and analyze digital evidence. Its main customers are law enforcement, defense, intelligence, and other public sector agencies.

Why does FedRAMP matter for Cellebrite?

FedRAMP is a U.S. government cloud security approval. Cellebrite received FedRAMP High authorization in May 2026, which makes it easier for federal agencies to buy and use its cloud products for sensitive data.

Is Cellebrite an AI company now?

Artificial intelligence is becoming a big part of the story through products like Genesis and Guardian Investigate. The core business is still digital forensics, but management believes AI could eventually double the total addressable market.

What is the biggest risk for CLBT stock?

The biggest risk is execution around government sales. The stock relies heavily on smooth government spending, and the company is currently working to redomicile to the United States to fix procurement hurdles.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 15, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Cellebrite 2025 Form 20-F
  2. Cellebrite Q2 2026 earnings transcript
  3. Cellebrite Q3 2026 earnings transcript
08 Explore the industry

Comparable Software - Infrastructure companies

Companies near Cellebrite DI Ltd. in Finn's Software - Infrastructure industry ranking.

Get started with Finn today